Clinical trials
Phase 2 clinical trials
Below are recruiting phase 2 clinical trials, each written for real people, not researchers. We’re tracking 294 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06541847RecruitingPhase 2
Testing HLX-1502 for NF1 with Plexiform Neurofibromas
This trial tests an experimental drug called HLX-1502 for people with NF1 who have a plexiform neurofibroma (a type of nerve tumor) that is growing or causing problems. It aims to see if the drug is safe and can shrink or stop the tumor from worsening.
Birmingham, AlabamaAges 12 years+ - NCT06553872RecruitingPhase 2
Pirtobrutinib and CAR T-cell therapy for mantle cell lymphoma
This trial tests if adding the targeted therapy pirtobrutinib before CAR T-cell treatment (Tecartus) works better for mantle cell lymphoma that has come back or not responded to other treatments. It aims to improve outcomes for patients who are eligible for CAR T-cell therapy.
Stanford, CaliforniaAges 18 years+ - NCT06561074RecruitingPhase 2
Study of calaspargase, decitabine, and venetoclax for young T-cell cancer
This trial tests a combination of three drugs (calaspargase, decitabine, and venetoclax) for children, teens, and young adults with T-cell leukemia or lymphoma that has come back or not responded to treatment. The goal is to see if this combination can help destroy cancer cells.
Houston, TexasAges 1 month–21 years - NCT06567743RecruitingPhase 2
Study of a new virus therapy for high-risk bladder cancer
This trial tests a new virus-based medicine, cretostimogene grenadenorepvec, given directly into the bladder for people with high-risk non-muscle-invasive bladder cancer. It may help prevent the cancer from coming back, especially for those who have not had BCG treatment or whose cancer did not respond to BCG.
Phoenix, ArizonaAges 18 years+ - NCT06568692RecruitingPhase 2
Study of PCS6422 with capecitabine for advanced breast cancer
This trial tests a new drug combination (PCS6422 plus capecitabine) for people with advanced or metastatic breast cancer that has not responded to other treatments. The goal is to see if adding PCS6422 can make the chemotherapy work better.
Tucson, ArizonaAges 18 years+ - NCT06592274RecruitingPhase 2
Study of HB0017 for people with plaque psoriasis
This trial tests an investigational drug, HB0017, in adults with moderate to severe plaque psoriasis. If you have had psoriasis for at least 6 months and have not used certain biologic treatments, you may be able to join.
Bengbu, AnhuiAges 18–75 - NCT07485725Recruiting
Digital tools study for health decisions
This study tests if digital tools can help older adults make better healthcare decisions. You’ll use a website to search for health information and share your thoughts in interviews.
Tallahassee, FloridaAges 60 years+ - NCT06655896RecruitingPhase 2
Rapcabtagene Autoleucel for severe diffuse scleroderma
This trial tests an investigational cell therapy called rapcabtagene autoleucel for people with severe diffuse cutaneous systemic sclerosis (a type of scleroderma that affects the skin and internal organs). The treatment uses your own modified immune cells to potentially calm the disease activity.
Los Angeles, CaliforniaAges 18–70 - NCT06607276RecruitingPhase 2
Adjuvant adebrelimab and capecitabine for high-risk bile duct cancer
This trial is for people with bile duct cancer who have had surgery to remove all visible cancer but are at high risk of it coming back. It tests whether adding two medications — adebrelimab (an immunotherapy) and capecitabine (a chemotherapy pill) — after surgery can help prevent the cancer from returning.
Nanjing, JiangsuAges 18–75 - NCT06621277Recruiting
Improving care for young adults with GI cancer
This study aims to improve care for younger adults (ages 18-50) with gastrointestinal (GI) tumors. Researchers will test ways to better support patients during and after treatment. If you are 18-50 and being treated for a GI tumor at Heidelberg University Hospital, you may be able to join.
Heidelberg, Baden-WurttembergAges 18 years+ - NCT06627738RecruitingPhase 2
Extra radiation boost for advanced lung cancer after standard treatment
This trial tests whether adding a precise, high-dose radiation boost (CyberKnife) after standard chemoradiation can improve outcomes for people with stage III non-small cell lung cancer that cannot be surgically removed. It is for those who have already completed two cycles of induction chemo and at least 40 Gy of radiation with chemo.
NiceAges 18 years+ - NCT06632262RecruitingPhase 2
Testing new drugs for cancers with FGFR gene changes
This trial tests two new drugs, ABSK061 and ABSK043, in people whose cancers have specific changes in the FGFR2 or FGFR3 genes. It may be an option if your cancer has stopped responding to standard treatments or if no standard treatment is available.
Guiyang, GuizhouAges 18 years+ - NCT06650514RecruitingPhase 2
OMO-103 for advanced osteosarcoma
This trial tests a new drug called OMO-103, which targets a protein called Myc that helps cancer cells grow. It is for people with advanced osteosarcoma (bone cancer) that has worsened after standard chemotherapy. The drug is given intravenously (through a vein), and the study will check if it is safe and shrinks tumors.
BarcelonaAges 12 years+ - NCT06680830RecruitingPhase 2
Testing NEU-411 for early Parkinson's with LRRK2 gene change
This trial tests an experimental drug called NEU-411 for people with early Parkinson's disease who have a specific genetic change (LRRK2). It aims to see if the drug can slow the disease progression.
Sun City, ArizonaAges 40–80 - NCT06695845RecruitingPhase 2
Study of zanidatamab for HER2-positive solid tumors
This trial tests a drug called zanidatamab in people with advanced solid tumors that have high levels of HER2 protein (called HER2-positive). It aims to see if zanidatamab can shrink or slow the growth of these tumors.
Prescott, ArizonaAges 18 years+ - NCT06703255RecruitingPhase 1/Phase 2
Testing HX301 for advanced high-grade glioma
This trial tests an experimental drug called HX301 for people with high-grade gliomas (fast-growing brain tumors). It is for patients whose tumor has come back after temozolomide chemo, or for those with newly diagnosed glioblastoma that has been surgically removed. The study aims to see if HX301 can help control the tumor.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06566742RecruitingPhase 2
Olutasidenib for IDH1-mutated blood disorders
This trial tests an oral drug called olutasidenib in people with certain low-risk blood cancers or a pre-cancer condition. It may help by targeting a specific genetic change (IDH1 mutation) found in your blood cells.
Miami, FloridaAges 18 years+ - NCT06226883RecruitingPhase 2
Testing MORF-057 for moderate to severe Crohn's disease
This study tests an oral medicine called MORF-057 for people with moderate to severe Crohn's disease. It aims to see if the drug can reduce inflammation and improve symptoms for those who haven't had success with other treatments.
Lancaster, CaliforniaAges 18–85 - NCT06708949RecruitingPhase 2
Immunotherapy combo for advanced kidney cancer
This trial compares two immunotherapy combinations—nivolumab/relatlimab/ipilimumab vs. nivolumab/ipilimumab—as first treatment for advanced kidney cancer with clear cell features. It aims to see which combo works better for people who haven't had prior therapy.
Boston, MassachusettsAges 18 years+ - NCT06745583RecruitingPhase 2
Testing an oral drug for brain inflammation in Alzheimer's
This study tests an experimental oral medication (EI-1071) to see if it can reduce brain inflammation in people with Alzheimer's disease. The goal is to learn if it is safe and might help slow cognitive decline.
TaipeiAges 50–85 - NCT06747923RecruitingPhase 2
SB17170 for Idiopathic Pulmonary Fibrosis (IPF)
This trial tests a new drug, SB17170, for people with IPF. It aims to see if the drug can help slow down lung damage. You may be eligible if you have a confirmed diagnosis of IPF and meet certain lung function criteria.
GoyangAges 40 years+ - NCT06786234RecruitingPhase 2
STP938 for high-risk essential thrombocythemia
This trial tests a daily pill called STP938 (dencatistat) for people with high-risk essential thrombocythemia (ET) who cannot take or have stopped responding to hydroxycarbamide. The goal is to see if STP938 can safely lower your platelet count and control the condition.
Poitiers, New AquitaineAges 18 years+ - NCT06794645RecruitingPhase 2
Pembrolizumab and Pemetrexed for Growing Chordoma
This trial tests two drugs—pembrolizumab (Keytruda) and pemetrexed—for people with chordoma that has continued to grow. The goal is to see if the combination can slow or stop the tumor. You'll need to be in fairly good health and able to take other medicines (folic acid and vitamin B12) to protect your body from side effects.
Santa Monica, CaliforniaAges 18 years+ - NCT06797401RecruitingPhase 2
RBD5044 for mixed high cholesterol and triglycerides
This trial tests a new medication called RBD5044 for people with mixed dyslipidemia (high levels of fats and cholesterol in the blood). It may help lower triglycerides and cholesterol when statins aren't enough.
LundAges 18–80
Hear when a new Phase 2 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for phase 2?
- Yes. Clin2 currently lists 294 recruiting phase 2 studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a phase 2 trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a phase 2 trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.